Last reviewed 2026-04-23 · How we verify

CC-97540

CC-97540 is a monoclonal antibody targeting CD47.

CC-97540 is a monoclonal antibody targeting CD47. Used for Relapsed or refractory multiple myeloma.

At a glance

Mechanism of action

CD47 is a protein that inhibits phagocytosis, and by targeting it, CC-97540 aims to enhance the immune system's ability to recognize and eliminate cancer cells.

Approved indications

• Relapsed or refractory multiple myeloma

Common side effects

• Fatigue
• Nausea
• Diarrhea

Key clinical trials

• A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) (PHASE2)
• A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis (PHASE3)
• A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) (PHASE1)
• CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis (PHASE1, PHASE2)
• A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) (PHASE1)
• A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.